NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT00154388 2016-11-18Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesNovartisPhase 2 Completed185 enrolled